Melbourne, Australia; 1 April 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that Dr Jeff Davies has commenced as an independent non-executive director, effective 1 April 2022.  

Dr Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland. Dr Davies’ experience spans R&D, business operations, drug development and product commercialisation.

Commenting on his appointment, Dr Davies said:

“I am delighted to join Starpharma’s board having been impressed by the company and its technology for a number of years as a shareholder. Starpharma’s deep portfolio of DEP^® oncology products and partnerships are particularly impressive.

“I also consider VIRALEZE™ to be a really interesting product opportunity and its rapid development and launch is a testament to Starpharma’s capable team.  Having held various roles at CSL across three decades,  I recognise the value of Starpharma’s technology, strategy and its innovative products, which have the potential to drive significant commercial value. I look forward to working with the Board and management team at this exciting time for Starpharma.”

An Appendix 3X Initial Director’s Interest Notice is attached.

Download full announcement here: Dr Jeff Davies appointed as non-executive director (PDF 129KB)